<li>doripenem<p>doripenem decreases levels of divalproex sodium by unknown mechanism. Avoid or Use Alternate Drug. Risk of seizure. Possible decreased GI absorption and/or increased renal clearance of valproic acid.</p></li><li>ertapenem<p>ertapenem decreases levels of divalproex sodium by unknown mechanism. Avoid or Use Alternate Drug. Risk of seizure. Possible decreased GI absorption and/or increased renal clearance of valproic acid.</p></li><li>imipenem/cilastatin<p>imipenem/cilastatin decreases levels of divalproex sodium by unknown mechanism. Avoid or Use Alternate Drug. Risk of seizure. Possible decreased GI absorption and/or increased renal clearance of valproic acid.</p></li><li>meropenem<p>meropenem decreases levels of divalproex sodium by unknown mechanism. Avoid or Use Alternate Drug. Risk of seizure. Possible decreased GI absorption and/or increased renal clearance of valproic acid.</p></li><li>sodium oxybate<p>divalproex sodium increases levels of sodium oxybate by Other (see comment). Avoid or Use Alternate Drug. 
Comment: If stabilized on sodium oxybate, decrease nightly dose by at least 20% when starting divalproex sodium; if already taking divalproex sodium, use a lower starting sodium oxybate dose; monitor dose and adjust dose accordingly.</p></li><li>sodium phenylacetate<p>divalproex sodium decreases effects of sodium phenylacetate by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Valproic acid may exacerbate hyperammonemia in pts. with urea cycle disorders.</p></li><li>vorinostat<p>vorinostat, divalproex sodium. pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of severe thrombocytopenia and GI bleeding.  Monitor platelet count q 2 wks for first 2 months.</p></li>